Amgen Inc Stock as Big Money Enter, Sentiment at 1.22

May 16, 2018 - By Michele Cranor

Amgen Inc. (NASDAQ:AMGN) Corporate Logo

Positions for Amgen Inc (NASDAQ:AMGN)

In Q4 2017 Amgen Inc (NASDAQ:AMGN) big money sentiment increased to 1.22, according to Securities and Exchange Commission filings. That’s up 0.23, from 2017Q3’s 0.99. 649 investment managers increased or started new stock positions, while 531 sold and decreased equity positions in Amgen Inc so the sentiment is positive. Funds own 551.71 million shares, down from 555.05 million shares in 2017Q3. Funds holding Amgen Inc in top 10 changed to 48 from 70 for a decrease of 22. In total 73 funds closed positions, 458 reduced and 527 increased. Also 122 funds bought new Amgen Inc stakes.

Most Amgen Inc Shareholders

Valueworks Llc owns 51,635 shares in Amgen Inc as of Q4 2017. As of Q4 2017, 862,174 shares of Amgen Inc are owned by Tekla Capital Management Llc. Merriman Wealth Management Llc reported 134,297 shares. Smead Capital Management Inc. revealed 682,114 shares position in Amgen Inc. The New York-based fund Krensavage Asset Management Llc looks positive on Amgen Inc, possessing 87,477 shares.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.The firm is worth $115.64 billion. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.64.55 is the P/E ratio. The companyÂ’s products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism ; and Erenumab for the prevention of migraine.

The stock increased 1.53% or $2.62 during the last trading session, reaching $173.64.Amgen Inc. has volume of 2.03M shares. Since May 16, 2017 AMGN has risen 3.78% and is uptrending. AMGN underperformed the S&P500 by 7.77%.

Investors wait Amgen Inc. (NASDAQ:AMGN)’s quarterly earnings on July, 24., Faxor reports. Analysts predict $3.52 earnings per share, which is $0.25 up or 7.65 % from 2017’s $3.27 earnings per share. If reported the P/E will be 12.33 with $2.34B profit. After $3.47 EPS report last quarter, Wall Street now forecasts 1.44 % EPS growth of Amgen Inc..

Tompkins reported 13,007 shs stake. Tci Wealth Advsrs reported 0.81% stake. Covington Advsrs invested 0.76% in Amgen Inc. (NASDAQ:AMGN). Toth Fincl Advisory Corp holds 0.57% or 13,870 shs in its capital. Hall Laurie J Trustee holds 11,900 shs or 1.18% of its capital. Chelsea Counsel Communications accumulated 2.08% or 22,391 shs. Grand Jean Mngmt invested 0.14% of its capital in Amgen Inc. (NASDAQ:AMGN). Neuberger Berman Group Ltd Liability has invested 0.04% in Amgen Inc. (NASDAQ:AMGN). Rathbone Brothers Public Lc holds 0.4% or 55,999 shs in its capital. Roof Eidam And Maycock Adv accumulated 5,145 shs or 0.44% of the stock. Pettyjohn Wood White reported 6,585 shs or 0.41% of all its holdings. Newman Dignan And Sheerar invested 0.95% of its capital in Amgen Inc. (NASDAQ:AMGN). Blume Capital has 400 shs. Sumitomo Life Insurance stated it has 0.5% in Amgen Inc. (NASDAQ:AMGN). San Francisco Sentry Invest Grp Inc (Ca) has invested 0.49% of its capital in Amgen Inc. (NASDAQ:AMGN).

Amgen Inc. had 5 insider sales and 0 buys since December 12, 2017. This’s net activity of $1.37 million.

Amgen Inc. (NASDAQ:AMGN) Ratings Coverage

A total of 14 analysts rate Amgen Inc (NASDAQ:AMGN) as follows: 7 “Buy”, 7 “Hold” and 0 “Sell”. Тherefore 50% are bullish. (NASDAQ:AMGN) has 17 ratings reports on 16 May 2018 according to StockzIntelligence. On Wednesday, January 24 JP Morgan maintained the shares of AMGN in report with “Neutral” rating. On Friday, February 2 the rating was maintained by PiperJaffray with “Overweight”. On Friday, February 2 Morgan Stanley maintained Amgen Inc. (NASDAQ:AMGN) rating. Morgan Stanley has “Overweight” rating and $196 target. On Thursday, January 18 the firm earned “Buy” rating by Piper Jaffray. On Monday, February 5 the rating was downgraded by Atlantic Securities to “Hold”. On Thursday, April 5 the stock of Amgen Inc. (NASDAQ:AMGN) has “Equal-Weight” rating given by Barclays Capital. On Friday, February 2 the firm has “Market Perform” rating by BMO Capital Markets given. The stock rating was maintained by Cowen & Co with “Buy” on Thursday, February 1. On Monday, January 22 RBC Capital Markets maintained Amgen Inc. (NASDAQ:AMGN) rating. RBC Capital Markets has “Hold” rating and $189.0 target. On Monday, February 12 Mizuho maintained Amgen Inc. (NASDAQ:AMGN) rating. Mizuho has “Buy” rating and $200.0 target.

Another two news for Amgen Inc. (NASDAQ:AMGN) were recently posted by: Fool.com on May 15, 2018 with title “Better Buy: Amgen Inc. vs. Biogen Inc.”. The other Seekingalpha.com‘s article was titled “Expanded label for Amgen’s Repatha approved in Europe” and posted on May 16, 2018.

Amgen Inc. (NASDAQ:AMGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: